Jason Aryeh
Directeur/Membre du Conseil chez ORCHESTRA BIOMED HOLDINGS, INC.
Fortune : 8 M $ au 31/05/2024
Postes actifs de Jason Aryeh
Sociétés | Poste | Début | Fin |
---|---|---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Directeur/Membre du Conseil | 27/09/2006 | - |
Independent Dir/Board Member | 27/09/2006 | - | |
ANEBULO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/03/2021 | - |
Independent Dir/Board Member | 01/03/2021 | - | |
ORCHESTRA BIOMED HOLDINGS, INC. | Directeur/Membre du Conseil | 26/01/2023 | - |
Independent Dir/Board Member | 26/01/2023 | - | |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Directeur/Membre du Conseil | 13/05/2021 | - |
Orchestra BioMed, Inc.
Orchestra BioMed, Inc. Medical SpecialtiesHealth Technology Orchestra BioMed, Inc. develops therapies for cardiovascular diseases. The firm offers BackBeat CNT and Virtue SEB. The company was founded in 2017 and is headquartered in New Hope, PA. | Directeur/Membre du Conseil | 01/11/2018 | - |
Omicron Delta Epsilon
Omicron Delta Epsilon Miscellaneous Commercial ServicesCommercial Services Omicron Delta Epsilon operates as an academic honor society. The company was founded in 1963 and is headquartered in Fairhope, AL. | Corporate Officer/Principal | - | - |
Cytovia Holdings, Inc. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Jason Aryeh
Anciens postes connus de Jason Aryeh
Sociétés | Poste | Début | Fin |
---|---|---|---|
NOVELION THERAPEUTICS INC. | Président | 01/06/2012 | 01/08/2018 |
Cystic Fibrosis Foundation Therapeutics, Inc.
Cystic Fibrosis Foundation Therapeutics, Inc. BiotechnologyHealth Technology Part of Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Inc. engages in drug discovery and development. The company is based in Bethesda, MD. | Directeur/Membre du Conseil | 01/02/2011 | 01/02/2018 |
░░░ ░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░ ░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░ ░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ ░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Jason Aryeh
Colgate University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 15 |
Canada | 4 |
2 |
Opérationnelle
Director/Board Member | 13 |
Independent Dir/Board Member | 8 |
Chairman | 3 |
Sectorielle
Health Technology | 11 |
Finance | 3 |
Commercial Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
MYREXIS, INC. | Finance |
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
ANEBULO PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 14 |
---|---|
JALAA Equities LP
JALAA Equities LP Investment ManagersFinance JALAA Equities LP is an independent hedge fund manager headquartered in Greenwich, Connecticut. The firm was founded by Jason Aryeh in 1997 and manages assets of high net worth clients. | Finance |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Omicron Delta Epsilon
Omicron Delta Epsilon Miscellaneous Commercial ServicesCommercial Services Omicron Delta Epsilon operates as an academic honor society. The company was founded in 1963 and is headquartered in Fairhope, AL. | Commercial Services |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, Inc. Medical SpecialtiesHealth Technology CorMatrix Cardiovascular, Inc. develops and markets commercial medical devices. It offers CorMatrix CanGaroo, Vascular Repair, Pericardial Repair & Reconstruction, Tyke, and Cardiac Tissue Repair. The company was founded by David B. Camp and Robert G. Matheny in 2001 and is headquartered in Roswell, GA. | Health Technology |
Cystic Fibrosis Foundation Therapeutics, Inc.
Cystic Fibrosis Foundation Therapeutics, Inc. BiotechnologyHealth Technology Part of Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Inc. engages in drug discovery and development. The company is based in Bethesda, MD. | Health Technology |
Novelion Therapeutics, Inc.
Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
Old API Wind-down Ltd.
Old API Wind-down Ltd. Pharmaceuticals: MajorHealth Technology Aralez Pharmaceuticals Inc. engages in the development, acquisition, and commercialization of cardiovascular, pain, and other product therapies. It operates through the following geographical segments: United States and Canada. The company is founded on December 2, 2015, and is headquartered in Mississauga, Canada. | Health Technology |
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Orchestra BioMed, Inc.
Orchestra BioMed, Inc. Medical SpecialtiesHealth Technology Orchestra BioMed, Inc. develops therapies for cardiovascular diseases. The firm offers BackBeat CNT and Virtue SEB. The company was founded in 2017 and is headquartered in New Hope, PA. | Health Technology |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
Rio Grande Renewables LLC | |
Orchestra Biomed Holdings, Inc. | |
Cytovia Holdings, Inc. |
- Bourse
- Insiders
- Jason Aryeh
- Expérience